152 related articles for article (PubMed ID: 33876336)
1. Propionic Acid-Based PET Imaging of Prostate Cancer.
Zhang Z; Liu S; Ma H; Xiang X; Nie D; Hu P; Tang G
Mol Imaging Biol; 2021 Dec; 23(6):836-845. PubMed ID: 33876336
[TBL] [Abstract][Full Text] [Related]
2. PET Imaging of Hepatocellular Carcinomas:
Zhao J; Zhang Z; Nie D; Ma H; Yuan G; Su S; Liu S; Liu S; Tang G
Mol Imaging; 2019; 18():1536012118821032. PubMed ID: 30799682
[TBL] [Abstract][Full Text] [Related]
3. Validation of R-2-[
Zhang Z; Liu S; Ma H; Nie D; Wen F; Zhao J; Sun A; Yuan G; Su S; Xiang X; Hu P; Tang G
Mol Imaging Biol; 2019 Dec; 21(6):1127-1137. PubMed ID: 30847820
[TBL] [Abstract][Full Text] [Related]
4. 2-18F-Fluoropropionic acid as a PET imaging agent for prostate cancer.
Pillarsetty N; Punzalan B; Larson SM
J Nucl Med; 2009 Oct; 50(10):1709-14. PubMed ID: 19759108
[TBL] [Abstract][Full Text] [Related]
5. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
6. The Utility of [
Beinat C; Haywood T; Chen YS; Patel CB; Alam IS; Murty S; Gambhir SS
Mol Imaging Biol; 2018 Dec; 20(6):1015-1024. PubMed ID: 29736561
[TBL] [Abstract][Full Text] [Related]
7. Assessment of PET tracer uptake in hormone-independent and hormone-dependent xenograft prostate cancer mouse models.
Kukuk D; Reischl G; Raguin O; Wiehr S; Judenhofer MS; Calaminus C; Honndorf VS; Quintanilla-Martinez L; Schönberger T; Duchamp O; Machulla HJ; Pichler BJ
J Nucl Med; 2011 Oct; 52(10):1654-63. PubMed ID: 21859811
[TBL] [Abstract][Full Text] [Related]
8. A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer.
Oka S; Hattori R; Kurosaki F; Toyama M; Williams LA; Yu W; Votaw JR; Yoshida Y; Goodman MM; Ito O
J Nucl Med; 2007 Jan; 48(1):46-55. PubMed ID: 17204698
[TBL] [Abstract][Full Text] [Related]
9. A high-affinity [(18)F]-labeled phosphoramidate peptidomimetic PSMA-targeted inhibitor for PET imaging of prostate cancer.
Ganguly T; Dannoon S; Hopkins MR; Murphy S; Cahaya H; Blecha JE; Jivan S; Drake CR; Barinka C; Jones EF; VanBrocklin HF; Berkman CE
Nucl Med Biol; 2015 Oct; 42(10):780-7. PubMed ID: 26169882
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Ester Hydrolysis as a New Approach in Development of Positron Emission Tomography Tracers for Imaging Hypoxia.
Zhang L; Yao X; Cao J; Hong H; Zhang A; Zhao R; Zhang Y; Zha Z; Liu Y; Qiao J; Zhu L; Kung HF
Mol Pharm; 2019 Mar; 16(3):1156-1166. PubMed ID: 30676751
[TBL] [Abstract][Full Text] [Related]
11. [(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells.
Ono M; Oka S; Okudaira H; Nakanishi T; Mizokami A; Kobayashi M; Schuster DM; Goodman MM; Shirakami Y; Kawai K
Nucl Med Biol; 2015 Nov; 42(11):887-92. PubMed ID: 26278491
[TBL] [Abstract][Full Text] [Related]
12. Increased Prostate Cancer Glucose Metabolism Detected by
Lavallée E; Bergeron M; Buteau FA; Blouin AC; Duchesnay N; Dujardin T; Tiguert R; Lacombe L; Fradet V; Makao-Nguile M; Fradet Y; Beauregard JM; Pouliot F
Eur Urol Focus; 2019 Nov; 5(6):998-1006. PubMed ID: 29609897
[TBL] [Abstract][Full Text] [Related]
13. Comparison of [18 F]fluorocholine and [18 F]fluorodeoxyglucose for positron emission tomography of androgen dependent and androgen independent prostate cancer.
Price DT; Coleman RE; Liao RP; Robertson CN; Polascik TJ; DeGrado TR
J Urol; 2002 Jul; 168(1):273-80. PubMed ID: 12050555
[TBL] [Abstract][Full Text] [Related]
14. Pyruvate-lactate exchange and glucose uptake in human prostate cancer cell models. A study in xenografts and suspensions by hyperpolarized [1-
van Heijster FHA; Heskamp S; Breukels V; Veltien A; Franssen GM; Jansen KCFJ; Boerman OC; Schalken JA; Scheenen TWJ; Heerschap A
NMR Biomed; 2020 Oct; 33(10):e4362. PubMed ID: 32662543
[TBL] [Abstract][Full Text] [Related]
15. 177Lu-AMBA biodistribution, radiotherapeutic efficacy, imaging, and autoradiography in prostate cancer models with low GRP-R expression.
Maddalena ME; Fox J; Chen J; Feng W; Cagnolini A; Linder KE; Tweedle MF; Nunn AD; Lantry LE
J Nucl Med; 2009 Dec; 50(12):2017-24. PubMed ID: 19910427
[TBL] [Abstract][Full Text] [Related]
16. Anti-Tumorigenic Potential of a Novel Orlistat-AICAR Combination in Prostate Cancer Cells.
Wright C; Iyer AKV; Kaushik V; Azad N
J Cell Biochem; 2017 Nov; 118(11):3834-3845. PubMed ID: 28387458
[TBL] [Abstract][Full Text] [Related]
17. Comparison of three ¹⁸F-labeled carboxylic acids with ¹⁸F-FDG of the differentiation tumor from inflammation in model mice.
Wang H; Tang G; Hu K; Huang T; Liang X; Wu Z; Li S
BMC Med Imaging; 2016 Jan; 16():2. PubMed ID: 26754531
[TBL] [Abstract][Full Text] [Related]
18. Targeting fatty acid synthase with ASC-J9 suppresses proliferation and invasion of prostate cancer cells.
Wen S; Niu Y; Lee SO; Yeh S; Shang Z; Gao H; Li Y; Chou F; Chang C
Mol Carcinog; 2016 Dec; 55(12):2278-2290. PubMed ID: 26894509
[TBL] [Abstract][Full Text] [Related]
19. Effect of hypoxia on the uptake of [methyl-3H]choline, [1-14C] acetate and [18F]FDG in cultured prostate cancer cells.
Hara T; Bansal A; DeGrado TR
Nucl Med Biol; 2006 Nov; 33(8):977-84. PubMed ID: 17127170
[TBL] [Abstract][Full Text] [Related]
20. Ex-vivo biodistribution and micro-PET/CT imaging of 18F-FDG, 18F-FLT, 18F-FMISO, and 18F-AlF-NOTA-PRGD2 in a prostate tumor-bearing nude mouse model.
Cheng Z; Wei R; Wu C; Qing H; Jiang X; Lu H; Chen S; Li X; Xu G; Ai H
Nucl Med Commun; 2015 Sep; 36(9):914-21. PubMed ID: 25973694
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
